Caris Chong, Hendrick Tan, Cherie Vaz, Susan Mincham, Eugene Leong, Max Hoffman, Tee Lim
{"title":"立体定向消融放疗治疗I期肺癌:西澳大利亚单一机构的回顾性报告","authors":"Caris Chong, Hendrick Tan, Cherie Vaz, Susan Mincham, Eugene Leong, Max Hoffman, Tee Lim","doi":"10.15406/ijrrt.2023.10.00352","DOIUrl":null,"url":null,"abstract":"Objectives: Stereotactic ablative radiotherapy (SABR) is now standard management of stage I non-small cell lung cancer in patients who are not medically operable. The purpose of this study was to assess clinical outcomes in our single institution to review comparability with worldwide outcomes. Methods: The institutional database was screened for all patients with Stage I NSCLC treated in between September 2010 to November 2018 with SABR. Local control was defined on PET/CT or CT imaging and survival status retrieved from electronic medical records. Overall survival and local control were calculated using Kaplan-Meier method. Results: 93 patients were treated with SBRT for stage I NSCLC. Median follow up time was 30 months (range 1-99 months). Overall survival was 67% and local control was 91% at 3 years respectively. Toxicity included grade 1-2 pneumonitis (16.5%), chest wall pain (3.3%) and rib fracture (2.1%) Conclusion: In our local institution SABR for Stage I NSCLC is a safe and effective form of management of medically inoperable patients.","PeriodicalId":486498,"journal":{"name":"International journal of radiology & radiation therapy","volume":"19 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Stereotactic ablative radiotherapy for stage I lung cancer: a retrospective single institution report in Western Australia\",\"authors\":\"Caris Chong, Hendrick Tan, Cherie Vaz, Susan Mincham, Eugene Leong, Max Hoffman, Tee Lim\",\"doi\":\"10.15406/ijrrt.2023.10.00352\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objectives: Stereotactic ablative radiotherapy (SABR) is now standard management of stage I non-small cell lung cancer in patients who are not medically operable. The purpose of this study was to assess clinical outcomes in our single institution to review comparability with worldwide outcomes. Methods: The institutional database was screened for all patients with Stage I NSCLC treated in between September 2010 to November 2018 with SABR. Local control was defined on PET/CT or CT imaging and survival status retrieved from electronic medical records. Overall survival and local control were calculated using Kaplan-Meier method. Results: 93 patients were treated with SBRT for stage I NSCLC. Median follow up time was 30 months (range 1-99 months). Overall survival was 67% and local control was 91% at 3 years respectively. Toxicity included grade 1-2 pneumonitis (16.5%), chest wall pain (3.3%) and rib fracture (2.1%) Conclusion: In our local institution SABR for Stage I NSCLC is a safe and effective form of management of medically inoperable patients.\",\"PeriodicalId\":486498,\"journal\":{\"name\":\"International journal of radiology & radiation therapy\",\"volume\":\"19 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-05-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International journal of radiology & radiation therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15406/ijrrt.2023.10.00352\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of radiology & radiation therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15406/ijrrt.2023.10.00352","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Stereotactic ablative radiotherapy for stage I lung cancer: a retrospective single institution report in Western Australia
Objectives: Stereotactic ablative radiotherapy (SABR) is now standard management of stage I non-small cell lung cancer in patients who are not medically operable. The purpose of this study was to assess clinical outcomes in our single institution to review comparability with worldwide outcomes. Methods: The institutional database was screened for all patients with Stage I NSCLC treated in between September 2010 to November 2018 with SABR. Local control was defined on PET/CT or CT imaging and survival status retrieved from electronic medical records. Overall survival and local control were calculated using Kaplan-Meier method. Results: 93 patients were treated with SBRT for stage I NSCLC. Median follow up time was 30 months (range 1-99 months). Overall survival was 67% and local control was 91% at 3 years respectively. Toxicity included grade 1-2 pneumonitis (16.5%), chest wall pain (3.3%) and rib fracture (2.1%) Conclusion: In our local institution SABR for Stage I NSCLC is a safe and effective form of management of medically inoperable patients.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
